KA-3123-LD38

N/A

Report date: 2026/05/15 20:01:45

Base Information

Drug NameKA-3123-LD38
Drug Alias NameKA-3123-LD38
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)Biologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Linker > Cleavable linker
Mechanisms of ActionEpidermal growth factor receptor erbB1 antagonistsAnti-CD276DNA topoisomerase I inhibitors
TargetsEpidermal growth factor receptor erbB1CD276 antigenDNA topoisomerase I
Therapy Area/IndicationsSolid tumours
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesShanghai Escugen Biotechnology Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesShanghai Escugen Biotechnology Co Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumours
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A